Xiao Xiangzhu, Yuan Jue, Qing Liuting, Cali Ignazio, Mikol Jacqueline, Delisle Marie-Bernadette, Uro-Coste Emmanuelle, Zeng Liang, Abouelsaad Mai, Gazgalis Dimitris, Martinez Manuel Camacho, Wang Gong-Xian, Brown Paul, Ironside James W, Gambetti Pierluigi, Kong Qingzhong, Zou Wen-Quan
Department of Pathology and National Prion Disease, Pathology Surveillance Center, Case Western Reserve University, 2085 Adelbert Road, Cleveland, Ohio 44106, USA.
Department of Pathology and National Prion Disease, Pathology Surveillance Center, Case Western Reserve University, 2085 Adelbert Road, Cleveland, Ohio 44106, USA ; Department of Clinical and Experimental Medicine, Second University of Naples, Naples, Italy.
J Clin Cell Immunol. 2014 Aug;5(4). doi: 10.4172/2155-9899.1000240.
Differentiating iatrogenic Creutzfeldt-Jakob disease (iCJD) from sporadic CJD (sCJD) would be useful for the identification and prevention of human-to-human prion transmission. Currently, the diagnosis of iCJD depends on identification of a recognized source of contamination to which patients have been exposed, in addition to fulfilling basic requirements for the establishment of diagnosis of CJD. Attempts to identify differences in clinical manifestations, neuropathological changes and pathological prion protein (PrP) between iCJD and sCJD have been unsuccessful. In the present study, using a variety of more sophisticated methods including sucrose step gradient sedimentation, conformational stability immunoassay, protein misfolding cyclic amplification (PMCA), fragment-mapping, and transmission study, we show no significant differences in gel profiles, oligomeric state, conformational stability and infectivity of PrP between iCJD and sCJD. However, using PMCA, we find that convertibility and amplification efficiency of PrP is greater in iCJD than in sCJD in a polymorphism-dependent manner. Moreover, two protease-resistant PrP C-terminal fragments (termed PrP-CTF12/13) were detected in all 9 cases of sCJD but not in 6 of 8 cases of iCJD tested in this study. The use of fragment mapping- and PMCA-based assays thus provides a means to distinguish most cases of iCJD from sCJD.
区分医源性克雅氏病(iCJD)与散发性克雅氏病(sCJD),对于识别和预防人与人之间的朊病毒传播具有重要意义。目前,iCJD的诊断除了要满足克雅氏病诊断的基本要求外,还依赖于确定患者接触过的公认污染源。此前试图找出iCJD和sCJD在临床表现、神经病理变化及病理性朊病毒蛋白(PrP)方面差异的尝试均未成功。在本研究中,我们运用了多种更复杂的方法,包括蔗糖阶梯梯度沉降、构象稳定性免疫测定、蛋白质错误折叠循环扩增(PMCA)、片段映射及传播研究,结果显示iCJD和sCJD在PrP的凝胶图谱、寡聚状态、构象稳定性及感染性方面并无显著差异。然而,通过PMCA我们发现,iCJD中PrP的可转化性和扩增效率高于sCJD,且这种差异具有多态性依赖性。此外,在本研究检测的所有9例sCJD中均检测到了两种蛋白酶抗性PrP C末端片段(称为PrP - CTF12/13),而在8例iCJD中的6例中未检测到。因此,基于片段映射和PMCA的检测方法为区分大多数iCJD和sCJD病例提供了一种手段。